Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells
Maria Maddalena Laterza(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Ferdinando De Vita(University of Campania "Luigi Vanvitelli")
Cited by 7
Related Papers
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2019|282
Neo-adjuvant and adjuvant chemotherapy of gastric cancer
|Annals of Oncology|2007|63
Impact of a Cardio-Oncology Unit on Prevention of Cardiovascular Events in Cancer Patients
|ESC Heart Failure|2022|22
Expression of c-MET in Estrogen Receptor Positive and HER2 Negative Resected Breast Cancer Correlated with a Poor Prognosis
|Journal of Clinical Medicine|2022|13